Five promising digital health companies selected to scale new health technologies

Latest News

Five of Australia’s emerging digital health companies have been accepted into the ANDHealth+ commercialisation program and will scale their products nationally and internationally.

The program will provide the companies with up to $3.75 million in equity-free funding alongside hands-on support from a network of experts to help them scale their businesses.

The companies are Atmo Biosciences, Eugene, Humanetix, Immunosis, and Metabolic Health Solutions.

ANDHealth+ is funded by the federal government's Medical Research Future Fund (MRFF).

ANDHealth CEO and managing director Bronwyn Le Grice said, “ANDHealth+ is a highly competitive program and the selection panel has been impressed by the continual improvement in the quality of applications over time.”

“These five exceptional companies will receive highly targeted expert advice and mentoring from international industry leaders, specialised commercialisation expertise, and significant non-dilutive investment to generate the clinical and commercial evidence required to scale their digital health products and services nationally and internationally,” said Ms Le Grice.

“Since the first cohort five years ago, ANDHealth+ cohort companies have raised over $148 million in new funding and generated revenues in excess of $49 million, whilst impacting more than 640,000 new patients and generating jobs, clinical trials and commercial pilots,” she said.

Atmo Biosciences is commercialising the world’s first ingestible, gas-sensing capsule for providing insights into gut health and microbiome function. Atmo’s gas-sensing capsule continuously measures clinically important gaseous biomarkers as it travels through the gut, with the insights aiming to provide improved diagnosis, more personalised treatments and earlier relief of symptoms for gastrointestinal disorders.

Eugene aims to help people access genetic testing and make informed health decisions. The obstacle to scaling genetic testing in a medical setting is the shortage of clinical specialists. The company is creating a virtual care model where 95% of specialist clinical care is automated.

Humanetix's HX Health platform is powered by an artificially intelligent care engine that delivers clinical workflows and suggestive next actions based on over 160 unique health identifiers for the individual patient.

Immunosis is a clinical-stage start-up company developing diagnostic products for patients with life-threatening immune deficiencies. Its proprietary test method includes a software algorithm and test collection kit that integrates gene expression signatures and mutation information from a whole blood sample to assist clinicians in diagnosing patients with immune deficiencies and inform treatment decisions.

Metabolic Health Solutions (MHS), an integrated medical technology and digital health company, supports practitioners to deliver better metabolic health outcomes for patients, as poor metabolic health directly impacts many common chronic diseases. MHS is an ISO13485 manufacturer who have pioneered measurement-informed lifestyle solutions for obesity.